tiprankstipranks
Advertisement
Advertisement

SMMT Stock Latest News

Summit Therapeutics: KOL Backing for Ivonescimab in NSCLC Reinforces Buy Rating and Unchanged $41 Price Target
RatingsSummit Therapeutics: KOL Backing for Ivonescimab in NSCLC Reinforces Buy Rating and Unchanged $41 Price Target
6d ago
SMMT
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations
PremiumCompany Announcements
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations
11d ago
SMMT
Summit Therapeutics price target lowered to $15 from $17 at Jefferies
PremiumThe Fly
Summit Therapeutics price target lowered to $15 from $17 at Jefferies
11d ago
SMMT
Midday Fly By: Intel reports Q2 beat, Anduril in talks for $100B valuation
PremiumThe Fly
Midday Fly By: Intel reports Q2 beat, Anduril in talks for $100B valuation
11d ago
BP
EW
H.C. Wainwright keeps Neutral on Summit Therapeutics after Q2 report
PremiumThe Fly
H.C. Wainwright keeps Neutral on Summit Therapeutics after Q2 report
11d ago
SMMT
Summit Therapeutics price target lowered to $38 from $45 at Stifel
PremiumThe FlySummit Therapeutics price target lowered to $38 from $45 at Stifel
11d ago
SMMT
Summit Therapeutics price target lowered to $38 from $40 at Guggenheim
Premium
The Fly
Summit Therapeutics price target lowered to $38 from $40 at Guggenheim
11d ago
SMMT
Closing Bell Movers: Intel up 4% on Q2 earnings beat
Premium
The Fly
Closing Bell Movers: Intel up 4% on Q2 earnings beat
12d ago
EW
FIX
Summit Therapeutics Establishes $380 Million ATM Equity Program
PremiumCompany Announcements
Summit Therapeutics Establishes $380 Million ATM Equity Program
12d ago
8K
SMMT
Summit Therapeutics reiterates ‘substantial doubt’ as going concern
PremiumThe Fly
Summit Therapeutics reiterates ‘substantial doubt’ as going concern
12d ago
SMMT
Summit Therapeutics says will need to raise additional capital
PremiumThe Fly
Summit Therapeutics says will need to raise additional capital
12d ago
SMMT
Summit Therapeutics Reports Ivonescimab Progress and Strong Cash
PremiumCompany Announcements
Summit Therapeutics Reports Ivonescimab Progress and Strong Cash
12d ago
8K
SMMT
Summit Therapeutics: Enrollment in both HARMONi-3 cohorts complete
PremiumThe FlySummit Therapeutics: Enrollment in both HARMONi-3 cohorts complete
12d ago
SMMT
Summit Therapeutics reports Q2 EPS (28c), consensus (21c)
Premium
The Fly
Summit Therapeutics reports Q2 EPS (28c), consensus (21c)
12d ago
SMMT
Summit Therapeutics options imply 6.5% move in share price post-earnings
Premium
The Fly
Summit Therapeutics options imply 6.5% move in share price post-earnings
12d ago
SMMT
Buy Rating Reaffirmed on Robust HARMONi Data and BLA Progress; $40 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Robust HARMONi Data and BLA Progress; $40 Price Target Maintained
12d ago
SMMT
Arcus, Summit enter into clinical trial collaboration over kidney cancer
PremiumThe Fly
Arcus, Summit enter into clinical trial collaboration over kidney cancer
13d ago
RCUS
SMMT
Summit Therapeutics Reports Positive Phase III Lung Cancer Data
PremiumCompany Announcements
Summit Therapeutics Reports Positive Phase III Lung Cancer Data
13d ago
8K
SMMT
Summit Therapeutics reports results from global Phase III HARMONi clinical trial
PremiumThe Fly
Summit Therapeutics reports results from global Phase III HARMONi clinical trial
13d ago
SMMT
SMMT Earnings this Week: How Will it Perform?
PremiumPre-EarningsSMMT Earnings this Week: How Will it Perform?
15d ago
SMMT
Summit Therapeutics signs agreement to sell ridinilazole to Biossil
Premium
The Fly
Summit Therapeutics signs agreement to sell ridinilazole to Biossil
21d ago
SMMT
Citizens healthcare analysts hold an analyst/industry conference call
Premium
The Fly
Citizens healthcare analysts hold an analyst/industry conference call
28d ago
CTMX
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >